This testing identified an expanded pathway-altered subgroup of FAKTION participants whose tumours carried a PIK3CA mutation or AKT1 E17K or deleterious PTEN alteration, as well as the corresponding expanded pathway non-altered subgroup. This evidence concerns the gene AKT1 and neoplasm.